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Abstract
Background: Conventional cytogenetic and comparative genomic hybridization (CGH) studies in brain malignancies have
shown that glioblastoma multiforme (GBM) is characterized by complex structural and numerical alterations. However, the
limited resolution of these techniques has precluded the precise identification of detailed specific gene copy number alterations.
Results: We performed a genome-wide survey of gene copy number changes in 20 primary GBMs by CGH on cDNA
microarrays. A novel amplicon at 4p15, and previously uncharacterized amplicons at 13q32-34 and 1q32 were detected and are
analyzed here. These amplicons contained amplified genes not previously reported. Other amplified regions containg well-
known oncogenes in GBMs were also detected at 7p12 (EGFR), 7q21 (CDK6), 4q12 (PDGFRA), and 12q13-15 (MDM2 and CDK4).
In order to identify the putative target genes of the amplifications, and to determine the changes in gene expression levels
associated with copy number change events, we carried out parallel gene expression profiling analyses using the same cDNA
microarrays. We detected overexpression of the novel amplified genes SLA/LP and STIM2 (4p15), and TNFSF13B and COL4A2
(13q32-34). Some of the candidate target genes of amplification (EGFR, CDK6, MDM2, CDK4, and TNFSF13B) were tested in an
independent set of 111 primary GBMs by using FISH and immunohistological assays. The novel candidate 13q-amplification target
TNFSF13B was amplified in 8% of the tumors, and showed protein expression in 20% of the GBMs.
Conclusion: This high-resolution analysis allowed us to propose novel candidate target genes such as STIM2 at 4p15, and
TNFSF13B or COL4A2 at 13q32-34 that could potentially contribute to the pathogenesis of these tumors and which would
require futher investigations. We showed that overexpression of the amplified genes could be attributable to gene dosage and
speculate that deregulation of those genes could be important in the development and progression of GBM. Our findings
highlight the important influence in GBM of signaling pathways such as the PI3K/AKT, consistent with the invasive features of
this tumor.
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Background
Glioblastoma multiforme (GBM) is the commonest and
most malignant of the primary central nervous system
tumors in the human adult. Mean survival of GBM
patients treated with the current standard therapy is
approximately one year [1].
Glioblastomas, like other solid tumors, are characterized
by changes in the expression of oncogenes and tumor sup-
pressor genes, often as a consequence of numerical chro-
mosomal abnormalities (genomic amplifications, gains,
and losses) that occur during the tumoral process. Con-
ventional and molecular cytogenetic techniques, such as
comparative genomic hybridization (CGH), have led to
the identification of recurrent genomic copy number
changes that play an important role in the malignancy of
GBM. Aberrations that occur with high frequency include
gains of chromosomes 7, 19, and 20, and losses of chro-
mosomes 6q, 9p, 10, 13q, and 14q [2,3]. Nevertheless,
the low resolution of these techniques, which is restricted
to the chromosome level, together with the large number
of genes located within these regions, makes difficult the
identification of candidate genes.
High-level DNA copy number changes in tumors are
restricted to chromosome regions that show more than 5-
to 10-fold copy number increases (regions of amplifica-
tion, or amplicons). Some of these amplicons contain
well-known oncogenes that are also overexpressed. While
this is the case for oncogenes associated with the develop-
ment of GBM, such as Epidermal Growth Factor Receptor
(EGFR)  (7p12),  Cyclin-Dependent Kinase 4 (CDK4)
(12q14), and the human homolog of the Mouse Double
Minute 2 (MDM2) (12q15) [2-4], other regions of ampli-
fication and/or other relevant genes located within these
or other regions remain unknown or incompletely
described.
New high-throughput genomic technologies, such as
cDNA microarray CGH [5], use conventional cDNA
microarrays that are normally used in expression profil-
ing, to examine genomic copy number imbalances. In this
way, thousands of genes can be reviewed in a high-resolu-
tion analysis to define amplicons and identify candidate
genes showing recurrent genomic copy number changes.
Parallel expression profiling experiments then allows the
identification of relevant target genes whose aberrant
expression could suggest its involvement in the pathogen-
esis of the tumors [6-10].
The objective of our study was to define at high resolution
regions of amplification in GBMs, and through integra-
tion of copy number and gene expression data, to identify
possible candidate target genes that could give insights
into the pathology of GBM. In addition, we also aimed to
analyze in detail the gene copy number changes associ-
ated with these tumors, since this is not feasible using clas-
sic chromosomal CGH.
For that purpose, we surveyed for changes in DNA copy
number and expression levels throughout the genomes of
20 primary GBMs by using cDNA microarray CGH and
expression profiling experiments. The most significant
alterations found were validated in additional series of
primary GBMs using locus-specific fluorescence in situ
hybridization (FISH), and immunohistochemical analy-
ses.
Methods
Patients and tissue samples
The genomic-profiling study involved 20 cases of primary
GBMs. Expression profiling experiments were carried out
in 17 of the GBMs for which RNA material was available.
Thirteen of the patients were males and 7 were females
with a mean age of 61 years (range, 39 to 81 years). The
clinical information of the patients is summarized in
Table 1.
To validate our results, 111 primary GBMs were arrayed in
tissue microarrays (TMAs) and subjected to immunohis-
tochemical and FISH analyses. Samples were collected
from Virgen de la Salud Hospital (Toledo, Spain), Clinic
Hospital (Barcelona, Spain) and Xeral-Cies Hospital
(Vigo, Spain). All samples were reviewed by means of tis-
sue sections stained with hematoxylin and eosin (H&E) to
verify tumor viability and confirm the diagnosis according
to the WHO guidelines by M.M., T.R., C.F., and F.-I.C.
cDNA microarray CGH and expression profiling
The cDNA microarrays used in this study (Oncochip v2.0)
were purchased from Centro Nacional de Investigaciones
Oncológicas [11]. These microarrays contained 27,454
cDNA clones, including 9,900 known genes and unchar-
acterized ESTs related to tumorigenesis.
High molecular weight genomic DNA from tumors and
normal human lymphocytes (used as reference DNA)
were extracted following standard phenol/chloroform
purification protocols. CGH experiments on cDNA micro-
arrays were performed as described [5,10,12]. Briefly, 20
μg of genomic tumoral and reference DNAs were digested
for 14–18 hours with AluI and RsaI (Life Technologies,
Inc., Rockville, MD) and purified by phenol-chloroform
extraction. Six μg of purified digested tumor DNA and ref-
erence DNA were labeled with Cy5-dUTP and Cy3-dUTP
(Amersham Biosciences, Piscataway, NJ), respectively,
using the Bioprime Labeling Kit (Life Technologies, Inc.).
Labeled tumor and sex-matched reference DNA were co-
hybridized at 58°C for 14–16 hours. Post-hybridization
washes were carried out in 2×S SC/0.03% SDS at hybridi-Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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zation temperature, 1× SSC and 0.2× SSC at room temper-
ature for 5 minutes each.
For expression profiling experiments total RNAs were
extracted with Tri Reagent (Molecular Research Center,
Cincinnati, OH) and amplified using a T7-based method,
as previously described (11). Five μgr of total RNA were
used to produce double-stranded cDNA (Superscript
Choice System, Life technologies, Inc.) and amplification
of mRNAs was performed using the Megascript T7 in vitro
transcription kit (Ambion, Austin, TX). A pool of aRNAs
obtained from the Universal Human RNA (Stratagene, La
Jolla, CA) was used as a standard reference in all hybridi-
zations. Test or reference amplified RNAs (aRNAs) were
labeled with fluorescent Cy5 and Cy3, respectively, and
hybridized at 42°C for 15 hours. Two control RNAs
obtained from non-tumoral brain (one of them from
Stratagene) were used for normalization purposes.
After hybridizations, slides were scanned using an Axon
GenePix 4100A confocal scanner. Image analysis was per-
formed using GenePix Pro 6.0 software (Axon Instru-
ments Inc., Union City, CA). Cy5/Cy3 fluorescence ratios
were normalized for each microarray using the print-tip
loess method and background subtraction with the Diag-
nosis and Normalization Array Data (DNMAD) tool [13].
Microarray data analysis
Data were preprocessed using Gene Expression Preproc-
essing Analysis Suite (GEPAS) [14] [see Additional file 1].
Cut-off points for defining gains and losses of genetic
material in the test hybridizations were established as
reported before [7,10]. The mean log2-transformed ratios
derived from the self versus self experiments of normal
genomic DNA in control hybridizations allowed us to
establish the cut-off points for defining gains and losses.
A value of the mean ratio +/- two standard deviations
showed a normal range of variation corresponding to
log2-transformed values of -0.42 to 0.42. In order to
ensure a fluorescence ratio of gain or loss, we considered
gene gain to be when log2 ratios were ≥ 0.5, and gene loss
to be when log2 ratios were ≤-0.5. Log2 fluorescent ratios ≥
2 were considered to represent gene amplification.
Fluorescence in situ hybridization and 
immunohistochemistry on TMAs
TMAs were constructed using formalin-fixed paraffin-
embedded archival tissue blocks as reported [15]. Five
non-tumoral controls (4 normal brain and one tonsil tis-
sue samples) were included. H&E-stained full sections
from each donor block were used for morphological selec-
tions of the representative areas of each case.
FISH assays were performed as described previously [15]
using gene-specific and control BAC clones selected from
the EnsEMBL [16] and UCSC [17] databases (Table 2).
Gene probes were labeled with SpectrumOrange-dUTP
(red) and control probes with SpectrumGreen-dUTP
(green) using the CGH Nick Translation Kit (Vysis).
Hybridizations were done overnight at 37°C after depar-
Table 1: Clinical and molecular data of the patients.
Case Sex Age Site OS Status 7p EGFR 1q 4p/4q 7q 12q CDK4 12q MDM2 13q -10q
C29 M3 9 T 4 6 A A
C34 F8 1P - O4 A AL
C35 M5 1 T 3 D AL
C35b F6 6 P 1 A AA L
C36 F5 5 T - P1 8 A AL
C38b F4 5 T - P 2 A AL
C42 M7 0 T - P - T A 2 D A
C47 M6 0 T 1 0 A A
C33 F6 1 T 1 6 D AA A L
C26 M5 2F - T - P3 D AA L
C36b M4 1 T 1 0 A AA L
C48 M7 4 T 7 D AA
C28 F7 7 T 4 D A
C39b M5 3 F 0 D AA L
C32 M6 0 T - P 8 D A
C30 M7 9 T - P 1 D
C31 M7 9 O 6 D
C37b M7 5 T 0 D L
C43 F5 3P - O3 A
C46 M5 9 T 9 D
Clinical data: sex (M male, F female), tumor site (T temporal, P parietal, O occipital, F frontal and T thalamus), overall survival (OS) in months, and 
status (D death, A Alive).
Molecular data: (A) amplification, (L) loss.Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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affinization of 4-μm-thick sections of the TMAs, target
retrieval by pressure-cooking with 1 mM EDTA for 10
minutes, and pepsin digestion (4 mg/ml at 37°C for 30
minutes). After post-hybridization washes, tissue was
counterstained with DAPI in antifade solution (Oncor,
Gaithersburg, MD).
Fluorescence signals were scored (Y.R., B.M.) in accord-
ance with previous reports [18]. In each sample, only well-
defined nuclei were analyzed, and the numbers of single-
copy gene and control probe signals were scored. Tumors
were considered as amplified when five or more unbal-
anced gene copies, or more than three times as many gene
signals as control signals were found in more than 5% of
tumor cells.
Immunophenotypic analysis was performed on deparaffi-
nized TMA sections. For antigen retrieval, a heating step in
a solution of 10 mM sodium citrate buffer at pH:6 in a
pressure cooker was included before incubation with anti-
bodies. Tissues were immunohistochemically stained by
the Labeled Streptavidin Biotin (LSAB) (DAKO, Glostrup,
Denmark), or alkaline phosphatase-conjugated EnVision
(DAKO) method, using the TechMate 500 (DAKO) auto-
matic immunostaining device. The primary antibodies
used were EGFR, MDM2 (Oncogene Research Products,
Boston, MA) and TNFSF13B (BAFF or BlySS). Tumors
were considered positive when membranous (EGFR),
nuclear (MDM2), and membrane-bound or cytoplasmic
(TNFSF13B) staining was observed in ≥ 5% of the tumor
cells.
Results
Impact of copy number alteration on gene expression
The gene frequencies of gain and loss of genetic material
found in the 20 primary GBMs were calculated, and plot-
ted relative to the position along the chromosome (Figure
1). Chromosomes 7, 19, and 20 most frequently showed
gains in copy number, while chromosomes 10 and 13
most frequently had losses (Table 3).
The global effect of copy number alterations on gene
expression was evaluated in 17 of the primary tumors. Up
to 33% of gained genes (>2.5-fold change in copy
number), or up to 56% with >4-fold, were overexpressed.
Nevertheless, 8% of the genes with normal copy numbers
were overexpressed (Figure 2A). Conversely, approxi-
mately 8% of the transcripts with high-level expression
(>10-fold) showed amplification (Figure 2B).
Gene amplifications in primary GBMs
Amplicons were identified on chromosomes 1, 4, 7, 12,
and 13 due to the presence of more than four contiguous
amplified genes. EGFR (7p12) was the most commonly
amplified gene (7p12), showing amplification by micro-
array CGH in 50% (10/20) of the GBMs (Table 1).
The amplicon detected on chromosome 13 in tumor 39
(Figure 3A) contained contiguous amplified clones cover-
ing a region of about 2.5 Mb at 13q32-34 that included
TNFSF13B (a ligand of the tumor necrosis factor super-
family), and collagen type IV genes (COL4A1  and
COL4A2). Among the amplified genes or ESTs, the most
important fold-changes in expression levels were those of
TNFSF13B, COL4A2 and FLJ10769. In addition, two other
tumors had centromeric-amplified clones including ESTs
AA706834, AA994053, and AI093016. However, these
ESTs were not overexpressed.
To determine the frequency of 13q amplification in a
larger series of tumors, we carried out FISH assays in an
independent set of 111 GBM samples. We found 8,5% of
tumors (6/70) showing amplification (Figure 3B, 3C). In
this same series, we examined the protein expression of
TNFSF13B as one of the putative target genes of the 13q
amplification. We detected TNFSF13B immunostaining
positivity in 20,6% of the samples (20/97). Half of the
13q-amplified tumors (3/6) showed TNFSF13B positive
expression, and 7 out of 59 (11,8%) non 13q-amplified
tumors showed TNFSF13B positivity (Figure 3D).
Table 2: Clones used for validation by FISH.
Gene name Gene-specific-BAC clones Location Control clones Location
EGFR RP11-339F13 7p12 p275α7a 7 cen
CDK4 RP11-571M6 12q13-q14 RP11-467M14 12p13
MDM2 RP11-611O2, RP11-450G15 12q15 RP11-467M14 12p13
ESTs on 13q RP11-94P17, RP11-406G20 13q32.2
RP11-364F8, RP11-151A6, RP11-113J24 13q33.3
a plasmid probe located at the centromere (cen) of chromosome 7. The specificity and location of the probes were confirmed by FISH on normal 
metaphases before hybridization on the TMAs. When clones were available, and in order to increase the signal, two or three BAC clones around 
the test gene or EST were hybridized together. Control FISH experiments on normal interphase nuclei were performed beforehand in order to 
ensure a unique signal when two BAC clones were hybridized together. BAC clones on 13q were purchased from the BACPAC Resources Center 
(Children's Hospital Oakland Research Institute, CHORI). All other clones were generously provided by Dr. Rocchi.Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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Amplicons were also detected on 1q, 4p, 4q, 7q, and 12q.
Chromosome 4 had two separated regions of amplifica-
tion (Figure 4A), one of about 6 Mb at 4p15, and the other
of approximately 2.2 Mb at 4q12. The 4p15 amplicon is
described here for the first time and contained several
genes and ESTs not previously reported as being amplified
in GBMs. The amplicon at 4q12 contained PDGFRA,
whose amplification in GBMs is already well known.
Among the amplified genes, SLA/LP, LOC389203, STIM2,
SGCB, RASL11B, and PDGFRA seem to respond to gene
dosage, presenting high fold-changes in expression levels
(Figure 4A). Likewise, amplification of several contiguous
clones on chromosome 1q32 included ATP2B4,
KIAA0663,  KISS1,  PPP1R15B,  PIK3C2B, and MDM4.
Among them, ATP2B4, KIAA0663, PPP1R15B, PIK3C2B
were overexpressed in the expression analyses (Figure 4B).
Chromosome 12 showed two regions of amplification at
12q13-15 (Table 4), one of about 180 Kb at 12q13 con-
taining CDK4 (10%, 2/19) and another one of about 700
Kb containing MDM2 (15%, 3/20) at 12q14.3-q15. These
results were validated by FISH analyses with specific
probes containing CDK4 or MDM2 and immunohisto-
chemical analyses for MDM2 onto paraffin sections of the
samples in a set of 111 primary GBMs, allowing confirma-
tion of the microarray results (Table 1). We found altera-
tions (either amplification or overexpression) of MDM2
and CDK4 in 11% of the tumors for which data were
available (11/98 and 7/66, respectively). Except for one
tumor, the two regions were not amplified simultane-
ously. These results suggest that MDM2 and CDK4 may be
independently amplified in most GBM tumors and con-
firm those of other authors [19]. Finally, amplification at
7q included PEX1, and CDK6 (7q21) as overexpressed
putative amplification targets (Table 5).
Discussion
The overall impact of copy number on gene expression
analyzed in GBMs reflects the importance of recurrent
gene copy number changes in the development and pro-
gression of these brain tumors. Our results in GBMs
extend previous studies in breast and prostate cancers
[10,20,21], and confirm that the effects of gene copy
number on expression levels were more relevant for high-
level amplifications on a gene-by-gene analysis (56% of
highly-gained genes were overexpressed).
Gene amplification is regarded to reflect genetic instabili-
ties in solid tumor cells [22]. It has been proposed that
activation of proto-oncogenes by amplification plays an
important role in the development of many human solid
tumors. Therefore, detection of specific gene amplifica-
tions in tumor cells can lead to the identification of genes
putatively involved in growth control and tumorigenesis.
While only a few candidate genes could be investigated at
a time in previous studies [4,23,24] we have used cDNA
microarray technology to search the whole genome for
gene copy number alterations in GBMs. Our results from
the approximately 10,000 genes and ESTs related to the
tumoral process that could be analyzed in this study, con-
firm the previous conclusion that EGFR is the principal
oncogene amplified in GBMs. However, in this study sev-
eral other chromosomal regions showing gene amplifica-
tion have also been detected in GBMs at 1q, 4p, 4q, 7q,
12q, and 13q. Amplification at 13q32-34 has been
reported before from chromosomal CGH studies in
malignant gliomas, cell lung carcinoma, head and neck
squamous carcinoma, and systemic lymphomas [20,25-
29]. Here we have used microarray CGH to study this
region at higher resolution (gene level) and have nar-
Frequency of copy number change Figure 1
Frequency of copy number change. (A) Frequency of gene amplification (black), gain (red), and loss (green) in the 20 
GBMs relative to their map position in the EnsEMBL database (calculated as the number of GBMs showing amplified, gained, or 
lost genes vs. the number of tumors analyzed for each gene). The white vertical bars represent the separation between chro-
mosomes. Only the most representative chromosomes are shown. Map positions for each cDNA clone were obtained from 
the EnsEMBL database using the IDconverter tool [45].
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rowed down the region to 2.5 Mb, showing that this
amplification could affect a small fraction of GBMs (8%).
Several known genes and uncharacterized ESTs are con-
tained in the 13q amplicon. Among these, COL4A2 has
also been found to be overexpressed in our study and in
other microarray expression-profiling studies of GBM
biopsies and GBM cell lines [30-32]. We speculate that
this overexpression may have been caused by amplifica-
tion of COL4A2, which may be a putative target of the
amplicon. In agreement with this hypothesis, very
recently, Tso and coworkers [33] have shown that
COL4A2 is one of 15 highly expressed genes that is shared
between primary and secondary GBMs. In addition, this
gene was found to be involved in glioma progression and
associated with vascular proliferation. However, immu-
nohistochemical analyses revealed that collagen IV is
mainly expressed in association with the tumor blood ves-
sels and not from the tumor cells [32], suggesting that the
COL4A2 overexpression detected in GBMs may not be as
a result of gene amplification in tumoral cells. This may
point out to TNFSF13B as a likely candidate for the target
of amplification. Immunohistochemical analyses of 111
primary GBMs revealed that TNFSF13B could be affected
in about 20% of the tumors. The TNFSF13B ligand (or
BAFF) is a member of the TNF cytokine family that acti-
vates nuclear factor (NF)-κB, phosphatidylinositol-3
kinase (PI3K)/AKT, and mitogen-activated protein kinase
(MAPK) pathways in myeloma multiple cells, and induce
strong up-regulation of Mcl-1 and Bcl-2 antiapoptotic
proteins [34].On another hand, the gene IRS2  (which
Table 3: Frequent copy number and expression altered genes1.
GAINED AND OVEREXPRESSED GENES
SYMBOL GENE DESCRIPTION % MEDIAN LOCATION
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 20.00 1.17 1q25-q32
LOC153222 Adult retina protein 25.00 1.32 5
GBAS Glioblastoma amplified sequence 20.00 1.61 7p12
GUSB Glucuronidase, beta 20.00 1.42 7q21.11
RFC2 Replication factor C (activator 1) 2, 40kDa 26.32 1.06 7q11.23
MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) 35.29 1.02 7q21.3-q22.1
GIMAP6 GTPase, IMAP family member 6 20.00 1.29
LR8 LR8 protein 21.05 2.34 7q36.1
APOE Apolipoprotein E 22.22 1.48 19q13.2
EMP3 Epithelial membrane protein 3 33.33 1.36 19q13.3
FPR1 Formyl peptide receptor 1 25.00 1.94 19q13.4
LOST AND UNDEREXPRESSED GENES
SYMBOL GENE DESCRIPTION % MEDIAN LOCATION
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 21.05 -2.87 2p21
TDE2 Tumor differentially expressed 2 23.53 -1.86 6q22.32
OPTN Optineurin 41.18 -1.86 10p14
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 25.00 -1.16 10
SIRT1 Sirtuin (silent mating type information regulation 2 homolog) 1 27.27 -1.27 10q22.1
PPP3CB Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform 35.00 -2.08 10q21-q22
GHITM Growth hormone inducible transmembrane protein 37.50 -1.55 10q23.2
CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1 21.05 -1.08 10q23-q24
LGI1 Leucine-rich, glioma inactivated 1 45.00 -1.32 10q24
SLK STE20-like kinase (yeast) 26.32 -1.11 10q25.1
ADD3 Adducin 3 (gamma) 68.42 -1.04 10q24.2-q24.3
MXI1 MAX interactor 1 40.00 -1.11 10q24-q25
ATRNL1 Attractin-like 1 30.77 -1.65 10
KIAA1598 KIAA1598 21.05 -1.83 10q26.12
NDFIP2 Nedd4 family interacting protein 2 33.33 -1.22 13q22.2
MAP2K4 Mitogen-activated protein kinase kinase 4 23.53 -1.30 17p11.2
DSG2 Desmoglein 2 31.25 -1.94 18q12.1
TPTE Transmembrane phosphatase with tensin homology 22.22 -1.67 21p11
1Percentage of tumors showing copy number and expression alterations (%). Median of expression log2 ratios of copy number altered genes 
(median).Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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codes a cytoplasmic adaptor protein that facilitates intrac-
ellular signal transduction) is also located within the
amplified region close to COL4A2  and  TNFSF13B.
Although we have no data available for this gene, one
study suggests that IRS2 is a novel but rare amplification
target at 13q34 in GBMs [35]. Thus, we propose here that
genes such as COL4A2 or TNFSF13B could be additional
putative targets for the 13q amplicon, and therefore
would warrant further detailed analyses in GBMs.
It is of particular note that two of the tumors showing this
amplification in the telomeric region of chromosome 13
had loss of the rest of the chromosome (Figure 3A), as was
also described by Weber and coworkers in the cases in
which amplification was revealed by chromosomal CGH
[36]. This finding is consistent with the finding that gene
amplification may be accompanied by loss of genetic
material in the proximity of the amplification site [37].
Chromosome 4 has two amplicons, located close
together. One contains PDGFRA as the putative target of
the amplicon, and the other contains SLA/LP, STIM2, and
two ESTs. To our knowledge, this is the first report of
amplification of SLA/LP and STIM2 genes, which are both
overexpressed. However, further analyses are required to
identify the amplification gene target(s) and to determine
the relevance of this novel amplification in GBM. STIM2
codes for a transmembrane phosphoprotein whose struc-
ture is unrelated to that of any other known protein [38]
and whose biological function has not been thoroughly
studied. STIM1 is the other member of this family of pro-
teins and it is thought to regulate cell growth control and
function within a signaling cascade, although the precise
pathway is not known [38].
There is controversy concerning the amplification on
chromosome 1, as to whether 1q32 has two independent
amplification targets or a single one affecting both MDM4
and  CNTN2  genes [39-41]. We observed amplification
covering a small region of about 800 Kb that excluded
CNTN2. Thus, our results support the proposal of Rie-
menschneider and coworkers that MDM4  is the main
amplification target gene at 1q32 [40]. However, other
genes among those contained in the amplicon, such as
PIK3C2B, which encodes a catalytic subunit of the PI3K,
could be of importance in GBMs. This gene was also
found amplified and overexpressed in GBMs by others
[32,41] and has a crucial role in the PI3K/AKT signaling
pathway, which regulates a number of cellular processes
such as cell growth and proliferation, apoptosis, migra-
tion and invasion, and angiogenesis [39]. Thus, our study
excludes CNTN2 and shows that other interesting candi-
date genes together with MDM4 may be important gene
targets for this 1q32 amplification.
Chromosome 7 was the most frequently gained chromo-
some in GBMs, as already known. Our results showed a
large number of overexpressed gained-chromosome 7
genes which may suggest the importance of the complete
gain of this chromosome in primary GBMs. Further stud-
ies, however, should be carried out to assess the impor-
tance of chromosome 7-candidate genes, other than
EGFR, in the pathogenesis of GBM. Likewise, chromo-
some 10 was the most frequently lost chromosome in
GBMs. The most frequently lost and underexpressed genes
mapped at 10q and involved candidate genes in gliomas
such as ADD3, between others. Downregulation of ADD3
expression was associated with increased migratory activ-
ity of human glioma cells in vitro [42], and decreased
expression of ADD3 has been described in astrocytomas
[43]. Chromosome 19 also showed frequent gene gains,
mainly located on 19q. One of the possible candidates
located in this chromosome could be FPR1 due to this
gene is expressed in malignant glioma and appears to
mediate motility, growth, and angiogenesis of GBM [44].
Conclusion
In summary, our results show that the cDNA microarray
CGH technique in parallel with expression profiling
allows the comprehensive, rapid and reliable analysis of
Impact of gene copy number on global gene expression levels Figure 2
Impact of gene copy number on global gene expres-
sion levels. (A) Percentage of over- or underexpressed 
genes (Y axis) according to copy number ratios (X axis). (B) 
Percentage of amplified and deleted genes according to 
expression ratios.
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Amplification at 13q Figure 3
Amplification at 13q. (A) DNA copy number and expression log2 ratios (black and red dots, respectively) of tumor 39b 
plotted according to the map position. Moving average of log2-genomic ratios over five neighboring genes are plotted and 
shown with a grey line. In the table below, amplified and overexpressed genes (in bold), with their corresponding log2-ratios, 
are detailed. Lost and amplified regions are indicated by green and red bars, respectively, under the graph. The amplified region 
at 13q32-34 is indicated by a grey square. (B) Amplification at 13q observed in one of the tumors of the TMA by using BAC 
probes located at 13q32.3 (labeled in red) and 13q33.2 (labeled in green). (C) Amplification on 13q32.3 in another GBM (BAC 
probes labeled in red). Amplified cells are indicated by arrows. (D) Photomicrograph of tumour tissue with positive expression 
for TNFSF13B showing cytoplasmic pattern (original magnification ×1000).Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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Amplification at chromosomes 4 and 1 Figure 4
Amplification at chromosomes 4 and 1. (A) DNA copy number ratios and expression log2 ratios (black and red dots, 
respectively) plotted with respect to their map position obtained for chromosome 4 of tumor 39b, and (B) for chromosome 1 
of tumor 35b. Average log2 genomic values over five neighboring genes are shown with a grey line as a function of the location 
of the clones. Described in the corresponding tables below each graph are the amplified and overexpressed (in bold) genes 
together with their corresponding copy number and expression log2 values.Molecular Cancer 2006, 5:39 http://www.molecular-cancer.com/content/5/1/39
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the whole genome in GBM tumors and enables the
refined and detailed study of amplicons and regions of
recurrent copy number change. This approach makes it
possible to identify putative glioma oncogenes/tumor-
suppressor genes that may deserve further investigation.
Our findings highlight the important influence in GBM of
signaling pathways such as the PI3K/AKT, consistent with
the invasive features of this tumor. In this context, we
identify candidate target genes of amplification that may
help to direct therapeutics for the treatment of GBM.
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